
Carlo Mario Lombardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5803551/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. Heart Failure Reviews, 2022, 27, 135-145.	1.7	2
2	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization — the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	0.8	21
3	Sex-related differences in patients with coronavirus disease 2019. Journal of Cardiovascular Medicine, 2022, Publish Ahead of Print, 254-263.	0.6	3
4	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 348.	1.0	5
5	Advanced heart failure: guidelineâ€directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Failure, 2022, 9, 1507-1523.	1.4	26
6	Prognostic significance of serum potassium in patients hospitalized for acute heart failure. ESC Heart Failure, 2022, 9, 2357-2366.	1.4	8
7	Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment. European Journal of Heart Failure, 2022, 24, 959-975.	2.9	23
8	Prognostic impact of the updated 2018 <scp>HFAâ€ESC</scp> definition of advanced heart failure: results from the <scp>HELPâ€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 1493-1503.	2.9	22
9	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	1.3	40
10	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clinical Research in Cardiology, 2021, 110, 1020-1028.	1.5	32
11	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 484-492.	2.5	41
12	Thrombotic risk in patients with COVID-19. Reviews in Cardiovascular Medicine, 2021, 22, 277.	0.5	6
13	A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance. ESC Heart Failure, 2021, 8, 1216-1229.	1.4	22
14	Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and betaâ€blockers in patients hospitalized for acute heart failure. ESC Heart Failure, 2021, 8, 1944-1953.	1.4	14
15	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. Europace, 2021, 23, 1603-1611.	0.7	34
16	The prognostic value of serial troponin measurements in patients admitted for COVIDâ€19. ESC Heart Failure, 2021, 8, 3504-3511.	1.4	25
17	Vericiguat for Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2021, 23, 144.	1.3	19
18	High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?. Journal of Cardiovascular Medicine, 2021, 22, 828-831.	0.6	4

CARLO MARIO LOMBARDI

#	Article	IF	CITATIONS
19	Congestion in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 575-586.	1.0	13
20	267 Cardiac biomarkers and mortality in COVID-19 infection. European Heart Journal Supplements, 2021, 23, .	0.0	0
21	261 A case of metastatic myxoid liposarcoma causing cardiac tamponade. European Heart Journal Supplements, 2021, 23, .	0.0	Ο
22	380 Left heart disease phenotype and use of pulmonary vasodilators in elderly patients with pulmonary arterial hypertension: the Patriarca registry. European Heart Journal Supplements, 2021, 23, .	0.0	0
23	566 Transthyretin and light-chain cardiac amyloidosis: clinical characteristics, echocardiographic findings, and outcomes of a large cohort of patients in Northern Italy. European Heart Journal Supplements, 2021, 23, .	0.0	0
24	278 Cardiac involvement in a 23 years old patient with granulomatosis with polyangiitis (GPA). European Heart Journal Supplements, 2021, 23, .	0.0	0
25	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	1.4	23
26	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. Cardiovascular Revascularization Medicine, 2020, 21, 857-864.	0.3	5
27	Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group. European Journal of Internal Medicine, 2020, 72, 47-52.	1.0	15
28	Targeting Cyclic Guanosine Monophosphate to Treat HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	1.2	71
29	June 2020 at a glance: focus on COVIDâ€19, quality of life and comorbidities. European Journal of Heart Failure, 2020, 22, 917-918.	2.9	5
30	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1274.	3.0	157
31	Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The "macro-hub―experience. IJC Heart and Vasculature, 2020, 31, 100662.	0.6	12
32	May 2020 at a glance: ischaemic heart failure and sexâ€related differences. European Journal of Heart Failure, 2020, 22, 761-762.	2.9	3
33	March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis. European Journal of Heart Failure, 2020, 22, 389-390.	2.9	1
34	Inâ€hospital and longâ€ŧerm mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Failure, 2020, 7, 2650-2661.	1.4	26
35	Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2020, 22, 1684-1693.	2.9	48
36	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977.	1.5	7

CARLO MARIO LOMBARDI

#	Article	IF	CITATIONS
37	January 2020 at a glance: translational medicine, predictors of outcome and treatments. European Journal of Heart Failure, 2020, 22, 1-2.	2.9	4
38	Acute heart failure: More questions than answers. Progress in Cardiovascular Diseases, 2020, 63, 599-606.	1.6	43
39	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	0.7	8
40	Left ventricular reverse remodelling predicts longâ€ŧerm outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. European Journal of Heart Failure, 2019, 21, 196-204.	2.9	47
41	October 2019 at a glance: epidemiology, prevention, and modes of death. European Journal of Heart Failure, 2019, 21, 1167-1168.	2.9	Ο
42	Highlights in heart failure. ESC Heart Failure, 2019, 6, 1105-1127.	1.4	109
43	November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment. European Journal of Heart Failure, 2019, 21, 1297-1298.	2.9	Ο
44	December 2019 at a glance: economic burden, coâ€morbidities, and prognosis. European Journal of Heart Failure, 2019, 21, 1485-1486.	2.9	1
45	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	2.9	24
46	Early readmission for heart failure: An avoidable or ineluctable debacle?. International Journal of Cardiology, 2019, 277, 186-195.	0.8	15
47	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	2.9	60
48	Endomyocardial fibrosis and myocardial infarction leading to diastolic and systolic dysfunction requiring transplantation. Cardiovascular Pathology, 2019, 38, 21-24.	0.7	1
49	Effects of ivabradine on endothelial function, aortic properties and ventricularâ€arterial coupling in chronic systolic heart failure patients. Cardiovascular Therapeutics, 2018, 36, e12323.	1.1	13
50	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	1.4	13
51	A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. International Journal of Cardiology, 2018, 250, 215-222.	0.8	3
52	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€ŧerm comparison. European Journal of Heart Failure, 2018, 20, 700-710.	2.9	84
53	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 365-375.	0.3	49
54	The need for evaluating right ventricular adaptation and ventriculo–arterial coupling. European Journal of Heart Failure, 2018, 20, 943-944.	2.9	0

CARLO MARIO LOMBARDI

#	Article	IF	CITATIONS
55	Iron deficiency in heart failure. Journal of Cardiovascular Medicine, 2018, 19, 706-716.	0.6	4
56	Updates in heart failure: what last year brought to us. ESC Heart Failure, 2018, 5, 989-1007.	1.4	10
57	Sacubitril/valsartan: from a large clinical trial to clinical practice. Journal of Cardiovascular Medicine, 2018, 19, 473-479.	0.6	8
58	Right heart dysfunction. Journal of Cardiovascular Medicine, 2018, 19, 613-623.	0.6	10
59	Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European Journal of Pharmacology, 2018, 838, 85-90.	1.7	19
60	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	1.9	94
61	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. Circulation, 2018, 138, 1088-1099.	1.6	253
62	Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	0.8	13
63	Assessment of Congestion in Acute Heart Failure: When Simplicity Does Not Go Along With Accuracy. Journal of Cardiac Failure, 2018, 24, 550-552.	0.7	1
64	Dobutamine stress echocardiography in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 270, 331-335.	0.8	11
65	Prognostic role of βâ€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	2.9	28
66	Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. International Journal of Cardiology, 2017, 234, 53-57.	0.8	45
67	Arrhythmias and cardiomyopathy. Journal of Cardiovascular Medicine, 2017, 18, e145-e148.	0.6	3
68	Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure. Journal of Cardiovascular Medicine, 2017, 18, 859-865.	0.6	13
69	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	1.0	33
70	Preoperative cardiac risks in noncardiac surgery: The role of coronary angiography. Monaldi Archives for Chest Disease, 2017, 87, 863.	0.3	9
71	Nutritional Deficiency in Patients with Heart Failure. Nutrients, 2016, 8, 442.	1.7	62
72	Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health. Nutrients, 2016, 8, 363.	1.7	88

#	Article	IF	CITATIONS
73	School and family-based interventions for promoting a healthy lifestyle among children and adolescents in Italy. Journal of Cardiovascular Medicine, 2016, 17, 547-555.	0.6	9
74	Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion?. European Journal of Heart Failure, 2016, 18, 1278-1286.	2.9	15
75	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	2.9	64
76	N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. Journal of Cardiovascular Medicine, 2016, 17, 828-839.	0.6	23
77	Novel insight into the dangerous connection between diabetes and heart failure. Herz, 2016, 41, 201-207.	0.4	12
78	Cardiorenal Interactions. Heart Failure Clinics, 2016, 12, 335-347.	1.0	11
79	In-hospital worsening heart failure in patients admitted for acute heart failure. International Journal of Cardiology, 2016, 225, 353-361.	0.8	16
80	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0	0 rgBT /O	verlock 10 T
81	Carnosine: Potential aid for diabetes and cardiovascular disease. Obesity, 2016, 24, 989-989	15	4

82	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 534-548.	0.4	28
83	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. Journal of Cardiac Failure, 2016, 22, 182-189.	0.7	118
84	Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure. Panminerva Medica, 2016, 58, 8-15.	0.2	6
85	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score –. Circulation Journal, 2015, 79, 2608-2615.	0.7	21
86	The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 597-602.	0.6	19
87	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	1.0	16
88	Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro–B-type natriuretic peptide levels: An individual patient data analysis. American Heart Journal, 2015, 170, 531-542.e1.	1.2	19
89	Serelaxin a novel treatment for acute heart failure. Expert Review of Clinical Pharmacology, 2015, 8, 549-557.	1.3	4
90	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. Nutrition, 2015, 31, 72-78.	1.1	56

#	Article	IF	CITATIONS
91	Amino acids and derivatives, a new treatment of chronic heart failure?. Heart Failure Reviews, 2015, 20, 39-51.	1.7	27
92	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	1.7	1
93	Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms. American Journal of the Medical Sciences, 2014, 347, 271-276.	0.4	23
94	Is There a Role for Ivabradine Beyond its Conventional Use?. Cardiovascular Therapeutics, 2014, 32, 189-192.	1.1	10
95	Renin-Angiotensin System Blockade and Worsening Renal Function in Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1114-1116.	1.2	3
96	N-3 PUFA increase bioavailability and function of endothelial progenitor cells. Food and Function, 2014, 5, 1881.	2.1	26
97	Effects of Oral Amino Acid Supplements on Functional Capacity in Patients with Chronic Heart Failure. Clinical Medicine Insights: Cardiology, 2014, 8, CMC.S14016.	0.6	37
98	Effect of Bosentan on Exercise Capacity and Clinical Worsening in Patients with Dual down and Eisenmenger Syndrome. Clinical Medicine Insights: Cardiology, 2013, 7, CMC.S10237.	0.6	16
99	Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?. Circulation: Heart Failure, 2012, 5, 54-62.	1.6	398
100	Response to Letter Regarding Article, "ls Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure? The Role of Congestion and Its Interaction With Renal Function― Circulation: Heart Failure, 2012, 5, .	1.6	3
101	Can we prevent or treat renal dysfunction in acute heart failure?. Heart Failure Reviews, 2012, 17, 291-303.	1.7	15
102	Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Failure Reviews, 2012, 17, 271-282.	1.7	25
103	Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clinical Research in Cardiology, 2012, 101, 663-672.	1.5	40
104	Sixâ€year prognosis of diabetic patients with coronary artery disease. European Journal of Clinical Investigation, 2012, 42, 376-383.	1.7	12
105	Use of Inotropic Agents in Patients with Advanced Heart Failure. Drugs, 2011, 71, 515-525.	4.9	15
106	Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION) Tj ETQq0 C Outcomes. American Journal of Cardiology, 2011, 108, 1449-1457.	0 rgBT /C 0.7	Overlock 10 Th 7
107	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. Cardiology, 2011, 119, 96-105.	0.6	56
108	Can we improve the treatment of congestion in heart failure?. Expert Opinion on Pharmacotherapy, 2011, 12, 1369-1379.	0.9	14

#	Article	IF	CITATIONS
109	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. Circulation: Heart Failure, 2011, 4, 724-732.	1.6	82
110	Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2010, 24, 49-60.	1.3	59
111	Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. International Journal of Cardiology, 2010, 144, 175-179.	0.8	61
112	Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Therapeutic Advances in Respiratory Disease, 2009, 3, 11-14.	1.0	8
113	Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. European Journal of Heart Failure, 2008, 10, 188-195.	2.9	331
114	Anemia and heart failure: a cause of progression or only a consequence?. Heart International, 2007, 3, 1.	0.4	0
115	Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Therapeutics and Clinical Risk Management, 2007, 3, 569-78.	0.9	6